Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that neuropeptides may contribute to the progression of alopecia areata by causing neurogenic inflammation and disrupting the inflammatory environment of hair follicles, but the exact pathogenesis still requires further investigation.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

In this study, researchers found that patients with alopecia areata had a significant increase in NKG2D+CD4+ T cell levels in their blood compared to healthy controls.

This study observed that inflammatory AIGA is associated with sweat duct inflammation and sweat coil atrophy, while non-inflammatory AIGA involves only sweat coil atrophy, suggesting distinct pathological features between the two.

This study suggests that immune privilege guardians and the pro-inflammatory cytokine interferon-γ significantly influence the dynamics of alopecia areata, supporting the hypothesis that immune privilege collapse is crucial in its development.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This review explores the potential role of caveolin-1 in cicatricial alopecia, particularly frontal fibrosing alopecia, and discusses possibilities for targeted therapies without providing new research results.

This study presents a rare case of alopecia totalis occurring after the use of permanent hair dye.

Hair loss treatment caused more hair loss in a man.

Sorafenib may cause hair loss in a way similar to alopecia areata.

This review discusses the association between oxidative stress and alopecia areata while proposing antioxidants as a potential supplementary therapy, but it reports no new clinical results.

This review discusses the biology and pathology of hair growth, exploring novel therapies like sublingual minoxidil and Janus kinase inhibitors, but reports no new clinical data.

This research suggests that innate lymphoid cells type 1 (ILC1) may contribute to the development of alopecia areata, alongside CD8+ T cells, by disrupting hair follicle immune privilege and promoting features of the disease.

This document includes a brief professional profile of Dr. Ralf Paus but presents no research findings or study results.

Winter-onset alopecia areata patients are more likely to regrow hair within a year compared to spring-onset patients.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

This review discusses the current understanding of frontal fibrosing alopecia's pathogenesis, highlighting genetic susceptibility, immune response involvement, and possible links to steroid hormones, but reports no new clinical results.

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

This case report describes a 25-year-old woman with alopecia areata and nail spooning, which regressed almost completely after treatment with oral corticosteroids.

The study suggests that immune privilege collapse in bulge cells and the involvement of pro-inflammatory cytokine interferon-γ contribute to hair follicle stem cell loss in lichen planopilaris.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This case study reports that a woman with epidermolysis bullosa acquisita experienced severe cicatricial alopecia and total nail loss after discontinuing treatment for two years, highlighting the potential for serious effects if the condition is not managed.

This review examines the pathophysiological mechanisms and emerging targeted treatments for alopecia areata, particularly highlighting the efficacy of oral JAK inhibitors over other less effective alternatives.

This article reviews treatments for alopecia areata, including corticosteroids and other immunomodulators, and reports no new experimental findings.

This review discusses new insights into the pathogenesis of alopecia areata related to perifollicular immune and endocrine factors and potential new treatments, but it reports no clinical results.

This study suggests that human dermal Vδ1+ γδ T-cells may contribute to alopecia areata pathogenesis by targeting stressed scalp hair follicles and inducing immune privilege collapse.

This review discusses the National Alopecia Areata Foundation's efforts to evaluate and advance alopecia areata research, focusing on immunology and drug development, and reports no new clinical results.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.